Revlimid

(Image: Getty/Seb_Ra)

BMS-Celgene mega-merger receives shareholder nod

By Ben Hargreaves

The $74bn deal appeared to be fraying around edges, as certain shareholders voiced dissent, but a vote saw the deal pass with support from more than 75% of investors.